Jones, J. D., Rajachandran, L., Yocca, F., Risinger, R., De Vivo, M., Sabados, J., Levin, F. R., & Comer, S. D. (2023). Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial. The American Journal of Drug and Alcohol Abuse, 49(1), 109–122. https://doi.org/10.1080/00952990.2022.2144743
Subjects:
Publication Type:
Article
Unique ID:
10.1080/00952990.2022.2144743
PMID:
Publication Date:
Data Source:
PubMed
Source Link: